SCHEMBL2214616

SCHEMBL2214616

O=C(c1ccc2[nH]ccc2c1)N1CCCCC1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.63
GHSR Q92847 2/20 0.59
GPR183 P32249 1/20 0.58
LMNA P02545 1/20 0.56
ALDH1A1 P00352 1/20 0.56
HPGD P15428 1/20 0.56
FASN P49327 1/20 0.55
DRD2 P14416 1/20 0.55
DRD3 P35462 1/20 0.55
MGLL Q99685 1/20 0.54
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
GFER P55789 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NUDT15 Q9NV35 1/20 0.52
OXTR P30559 1/20 0.51
CCR3 P51677 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3457123 1.00 MAPK14 (0.63) MAPK14GHSRGPR183LMNAALDH1A1
SCHEMBL29944365 1.00 MAPK14 (0.63) MAPK14GHSRGPR183LMNAALDH1A1
SCHEMBL8534513 0.98 MAPK14 (0.64) MAPK14GHSRGPR183LMNAALDH1A1
SCHEMBL30226931 0.98 MAPK14 (0.64) MAPK14GHSRGPR183LMNAALDH1A1
SCHEMBL30329646 0.95 MAPK14 (0.64) MAPK14GHSRGPR183LMNAFASN
SCHEMBL22216445 0.95 MAPK14 (0.64) MAPK14GHSRGPR183LMNAFASN
SCHEMBL29944074 0.89 GHSR (0.71) MAPK14GHSRALDH1A1HPGDNPC1
SCHEMBL1355458 0.89 GHSR (0.71) MAPK14GHSRALDH1A1HPGDNPC1
SCHEMBL3386763 0.87 MAPK14 (0.62) MAPK14GHSRGPR183FASNDRD2
SCHEMBL30066210 0.87 MAPK14 (0.62) MAPK14GHSRGPR183FASNDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345702-B1 PGDH inhibitors and methods of making and using MYOFORTE THERAPEUTICS, INC. (US) 2022-05-31 US disclosed
WO-2022082009-A1 INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF EPIRIUM BIO INC. (US) 2022-04-21 WO disclosed
US-11052377-B2 Supported metal catalyst TOYO GOSEI CO., LTD. (JP) 2021-07-06 US disclosed
US-20200290018-A1 SUPPORTED METAL CATALYST TOYO GOSEI CO., LTD. (JP) 2020-09-17 US disclosed
EP-2811990-B1 MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) UNIV TEXAS (US) 2017-10-25 EP disclosed
US-9539256-B2 Modulators of exchange proteins directly activated by cAMP (EPACS) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-01-10 US disclosed
US-9539256-B2 Modulators of exchange proteins directly activated by cAMP (EPACS) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-01-10 US disclosed
US-9539256-B2 Modulators of exchange proteins directly activated by cAMP (EPACS) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-01-10 US disclosed
US-9328125-B2 Bivalent AMPA receptor positive allosteric modulators THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-05-03 US disclosed
US-9328125-B2 Bivalent AMPA receptor positive allosteric modulators THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-05-03 US disclosed
US-20150110809-A1 MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-04-23 US disclosed
US-20150110809-A1 MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-04-23 US disclosed
US-20150057248-A1 BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-02-26 US disclosed
US-20150057248-A1 BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-02-26 US disclosed
WO-2013130501-A1 BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-09-06 WO disclosed
WO-2013119931-A1 MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-08-15 WO disclosed
US-20110178062-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2011-07-21 US disclosed
EP-2125720-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR Janssen Pharmaceutica, N.V. (BE) 2009-12-02 EP disclosed
EP-2108642-A1 JAK INHIBITOR Kyowa Hakko Kirin Co., Ltd. (JP) 2009-10-14 EP disclosed
WO-2008109333-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052377-B2 Supported metal catalyst SOD1, SOD3, SLC39A14 MAPK14 1865/4885GHSR 4509/4885GPR183 3582/4885
US-20110178062-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH1 MAPK14 2871/4885GHSR 508/4885GPR183 407/4885
US-20200290018-A1 SUPPORTED METAL CATALYST SOD1, SOD3, SLC39A14 MAPK14 1865/4885GHSR 4509/4885GPR183 3582/4885
US-20150110809-A1 MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) RAPGEF3, RAPGEF4, CREB1 MAPK14 1443/4885GHSR 1975/4885GPR183 1534/4885
US-11345702-B1 PGDH inhibitors and methods of making and using HPGD, HPGDS, PTGS1 MAPK14 2818/4885GHSR 1998/4885GPR183 1041/4885
US-20150057248-A1 BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS GRIK2, GABRE, GRIK4 MAPK14 3269/4885GHSR 363/4885GPR183 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.